Reports Q4 revenue $6.44B, consensus $6.36B. “We delivered another year of double-digit organic sales growth while continuing to expand adjusted operating margins and drive adjusted earnings per share growth,” said Kevin Lobo, chair and CEO, Stryker (SYK). “We also had many product launches and were active in M&A to further enhance our position in high-growth end markets. I would like to thank our teams for their efforts in delivering excellent results and positioning Stryker for sustained success in 2025 and beyond.”
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Notable companies reporting after market close
- Stryker options imply 3.8% move in share price post-earnings
- SYK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Needham medtech & diagnostics analyst holds analyst/industry conference call
- Stryker commences $80 per share cash offer for Inari Medical